Antiemetics: An update and the MASCC guidelines applied in clinical practice

Nature Clinical Practice Oncology

Volumn 5, Issue 1, 2008, Pages 32-43

  Herrstedt, Jørn ^a  

^a Mental Health Center Glostrup   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

2 BENZHYDRYL 3 (2 METHOXYBENZYLAMINO) 1 AZABICYCLO[2.2.2]OCTANE; ANTIEMETIC AGENT; APREPITANT; BEMESETRON; CANNABINOID; CISPLATIN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DIPHENHYDRAMINE; DOLASETRON MESILATE; DOPAMINE 2 RECEPTOR BLOCKING AGENT; DOXORUBICIN; DRONABINOL; EPIRUBICIN; GRANISETRON; HALOPERIDOL; LORAZEPAM; METOCLOPRAMIDE; METOPIMAZINE; NABILONE; NEUROKININ 1 RECEPTOR ANTAGONIST; ONDANSETRON; PALONOSETRON; PLACEBO; PROCHLORPERAZINE; SEROTONIN ANTAGONIST; TACHYKININ RECEPTOR ANTAGONIST; TROPISETRON; UNINDEXED DRUG; ANTINEOPLASTIC AGENT; NEUROTRANSMITTER RECEPTOR; NEW DRUG;

ADJUVANT THERAPY; BLOOD BRAIN BARRIER; BREAST CANCER; CHEMOTHERAPY INDUCED EMESIS; CLINICAL PRACTICE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONSTIPATION; DRUG ANTAGONISM; DRUG BIOAVAILABILITY; DRUG CHOICE; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG SAFETY; EVIDENCE BASED MEDICINE; EXTRAPYRAMIDAL SYMPTOM; HUMAN; LOW DRUG DOSE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SINGLE DRUG DOSE; UNSPECIFIED SIDE EFFECT; CHEMICALLY INDUCED DISORDER; CLASSIFICATION; DRUG EFFECT; FEMALE; MALE; NAUSEA; PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; STATISTICS; VOMITING;

ADRENAL CORTEX HORMONES; ANTIEMETICS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DRUGS, INVESTIGATIONAL; EVIDENCE-BASED MEDICINE; FEMALE; GUIDELINE ADHERENCE; HUMANS; MALE; NAUSEA; PRACTICE GUIDELINES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, NEUROTRANSMITTER; VOMITING;

EID: 38449089186     PISSN: 17434254     EISSN: 17434262     Source Type: Journal    
DOI: 10.1038/ncponc1021     Document Type: Review

References (96)

1. Landing BH et al. (1949) Systemic pathological effects of nitrogen mustards, and a comparison of toxicity, chemical structure and cytotoxic effect, with reference to the chemotherapy of tumors. Cancer 2 1055-1066
2. Coates A et a. (1983) On the receiving end - patient perception of the side-effects of cancer chemotherapy. Eur J Cancer Clin Oncol 19: 203-208
3. Thumas LJ (1892) Ueber das Brechcentrum und über die wirkung einiger pharmakologischer Mittel auf dasselbe. Archieves für Patologische Anatomie 123: 44-69
4. Hatcher RA and Weiss S (1923) Studies on vomiting. J Pharmacol Exp Ther 22: 139-193
5. Wang SC and Borison HL (1952) A new concept of organization of the central emetic mechanism: Recent studies on sites of action of apomorphine, copper sulphate and cardiac glycosides. Gastroenterology 22: 1-12
6. Borison HL and Wang SC (1953) Physiology and pharmacology of vomiting. Pharmacol Rev 5: 193-230
7. Lindstrom PA and Brizzee KR (1962) Relief of intractable vomiting from surgical lesions in the area postrema. J Neurosurg 19: 228-236
8. McCarthy LE and Borison HL (1984) Cisplatin-induced vomiting eliminated by ablation of the area postrema in cats. Cancer Treat Rep 68 401-404
9. Smith WL et al. (1988) The emetic activity of centrally administered cisplatin in cats and its antagonism by zacopride. J Pharm Pharmacol 40: 142-143
10. Miller AD and Wilson VJ (1983) "Vomiting center" reanalyzed: An electrical stimulation study. Brain Res 270: 154-158
11. Carpenter DO (1990) Neural mechanisms of emesis. Can J Physiol Pharmacol 68: 230-236
12. Miller AD et al. (1994) Brain areas essential or non-essential for emesis. Brain Res 647: 255-264
13. Yoshida N et al. (1995) A dopamine D3 receptor agonist, 7-OH-DPAT, causes vomiting in the dog. Life Sci 57: PL347-PL350
14. Yoshikawa T et al. (1996) Involvement of dopamine D3 receptors in the area postrema in R(+)-7-OH-DPAT-induced emesis in the ferret. Eur J Pharmacol 301: 143-149
15. Moertel CG et al. (1963) A controlled clinical evaluation of antiemetic drugs. JAMA 186: 116-118
16. Rapport MM et al. (1948) Crystalline serotonin. Science 108: 329-330
17. Gaddum JH and Picarelli ZP (1957) Two kinds of tryptamine receptor. Br J Pharmacol Chemother 12: 323-328
18. 3H]spiroperidol. Mol Pharmacol 16: 687-699
19. Bradley PB et al. (1986) Proposals for the classification and nomenclature of functional receptors for 5-hydroxytryptamine. Neuropharmacology 25: 563-576
20. Hoyer D et al. (1994) International Union of Pharmacology Classification of receptors for 5-hydroxytryptamine (serotonin). Pharm Exper Ther 46: 157-203
21. 3 receptors. Proc Natl Acad Sci USA 102: 12595-12600
22. 3 receptors in rat brain using radioligand binding. Nature 330 746-748
23. 3 receptors in mammalian hindbrain. TIPS 11: 135-137
24. Fozard JR and Mobarok ALI A (1978) Blockade of neuronal tryptamine receptors by metoclopramide. Eur J Pharmacol 49: 109-112
25. Gralla RJ et al. (1981) Antiemetic efficacy of high-dose metoclopramide: Randomized trials with placebo and prochlorperazine in patients with chemotherapy-induced vomiting. N Engl J Med 305 905-909.
26. Fozard JR (1984) MDL 72222, a potent and highly selective antagonist at neuronal 5-hydroxytryptamine receptors. Naunyn Schmiedebergs Arch Pharmacol 326: 36-44
27. Miner WD and Sanger GJ (1986) Inhibition of cisplatin-induced vomiting by selective 5-hydroxytryptamine M-receptor antagonism. Br J Pharmacol 88: 497-499
28. Costall B et al. (1986) 5-hydroxytryptamine M-receptor antagonism to prevent cisplatin-induced emesis Neuropharmacology 25: 959-961
29. 3 receptor-antagonist) in prevention of chemotherapy-induced emesis. Lancet 329: 1198
30. Von Euler VS and Gaddum JH (1931) An unidentified depressor substance in certain tissue extracts. J Physiol (Lond) 1931: 577-583
31. Chang M and Leeman SE (1970) Isolation of sialogogic peptide from bovine hypothalamic tissue and its characteristic as substance P. J Biol Chem 245: 4784-4790
32. Leander S et al. (1981) A specific substance P antagonist blocks smooth muscle contractions. induced by non-cholinergic, non-adrenergic nerve stimulation. Nature 294: 467-469
33. 1) receptor. Science 251: 435-437
34. 1 receptor antagonist CP-99,994 attenuates cisplatin induced emesis in the ferret. Eur J Pharmacol 250: R5-R6
35. 1 receptor antagonist to prevent delayed emesis after cisplatin. J Natl Cancer Inst 89: 817-818
36. Tsukusa M et al. (1995) Comparison of granisetron alone and granisetron plus hydroxyzine hydrochloride for prophylactic treatment of emesis induced by cisplatin chemotherapy. Eur J Cancer 31A: 1647-1649
37. Longo DL et al. (1982) Results of a randomized, double-blind crossover trial of scopolamine versus placebo administered by transdermal patch for the control of cisplatin-induced emesis. Cancer Treat Rep 66: 1975-1976
38. Herrstedt J et al. (1998) Corticosteroids, dopamine antagonists and other drugs. Support Care Cancer 6: 204-214
39. Baker JJ et al. (1979) Letter. N Eng J Med 301: 728
40. Dana BW et al. (1985) Dexamethasone vs. placebo for cisplatin-induced emesis: A randomized cross-over trial. Am J Clin Oncol 8: 426-428
41. Allan SG et al. (1984) Deaxamethasone and high-dose metoclopramide: Efficacy in controlling cisplatin-induced nausea and vomiting. BMJ 289: 878-879
42. Rolla F et al. (1991) Prevention of cisplatin-induced emesis: A double-blind multicenter, randomized crossover study comparing ondansetron and ondansetron plus dexamethasone. J Clin Oncol 9 675-678
43. Italian Group for Antiemetic Research (1995) Dexamethasone, granisetron or both for the prevention of nausea and vomiting during chemotherapy for cancer. N Engl J Med 332: 1-5
44. Roila F et al. (2005) Delayed emesis: Moderately emetogenic chemotherapy. Support Care Cancer 13: 104-108
45. Kris MG et al. (2005) Consensus proposals for the prevention of acute and delayed vomiting and nausea following high-emetic risk chemotherapy. Support Care Cancer 13: 85-96
46. Kris MG et al. (1985) Improved control of cisplatin-induced emesis with high-dose metoclopramide and with combinations of metoclopramide, dexamethasone, and diphenhydramine. Cancer 55: 527-534
47. 3 receptor antagonist. Lancet 329: 1461-1463
48. 3 (serotonin) antagonist ondansetron (GR 38032F) with high-dose metoclopramide in the control of cisplatin-induced emesis. N Engl J Med 322: 816-821
49. De Mulder PHM et al. (1990) Ondansetron compared with high-dose metoclopramide in prophylaxis of acute and delayed cisplatin-induced nausea and vomiting. Ann Intern Med 113: 834-840
50. Hainsworth J et al. (1991) A single-blind comparison of intravenous ondansetron, a selective serotonin antagonist, with intravenous metoclopramide in the prevention of nausea and vomiting associated with high-dose cisplatin chemotherapy. J Clin Oncol 9: 721-728
51. Bonneterre J et al. (1990)A randomized double-blind comparison of ondansetron and metoclopramide in the prophylaxis of emesis induced by cyclophosphamide, fluoropracil, and doxorubicin or epirubicin chemotherapy. J Clin Oncol 8: 1063-1069
52. Kaasa S et al. (1990) A comparison of ondansetron and metoclopramide in the prophylaxis of chemotherapy-induced nausea and vomiting: A randomized, double-blind study. Eur J Cancer 26: 311-314
53. Marschner NW et al. (1991) Double-blind randomized trial of the antiemetic efficacy and safety of ondansetron and metoclopramide in advanced breast cancer patients treated with epirubicin and cyclophosphamide. Eur J Cancer 27: 1137-1140
54. Jones AL et al. (1991) Comparison of dexamethasone and ondansetron in the prophylaxis of emesis induced by moderately emetogenic chemotherapy. Lancet 338: 483-487
55. Warr D et al. (1993) A randomized, double-blind comparison of granisetron with high-dose metoclopramide, dexamethasone and diphenhydramine for cisplatin-induced emesis. Eur J Cancer 29A 33-36
56. Warr D et al. (1991) Superiority of granisetron to dexamethasone plus prochlorperazine in the prevention of chemotherapy-induced emesis. J Natl Cancer Inst 83: 1169-1173
57. Geling O and Eichler H-G (2005) Should 5-hydroxytryptamine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? Systematic re-evaluation of clinical evidence and drug cost implications. J Clin Oncol 23: 1289-1294
58. Hesketh PJ et al. (1994) A randomized, double-blind comparison of intravenous ondansetron alone and in combination with dexamethasone in the prevention of high-dose cisplatin-induced emesis. J Clin Oncol 12: 596-600
59. Herrstedt J et al. (1993) Ondansetron plus metopimazine compared with ondansetron alone in patients receiving moderately emetogenic chemotherapy. N Engl J Med 328: 1076-1080
60. Herrstedt J et al. (1997) Randomized, double-blind comparison of ondansetron versus ondansetron plus metopimazine as antiemetic prophylaxis during cisplatinum-based chemotherapy in patients with cancer. J Clin Oncol 15: 1690-1696
61. Antiemetic Subcommittee of The Multinational Association of Supportive Care in Cancer (MASCC) (1998) Prevention of chemotherapy and radiotherapy-induced emesis: Results of the Perugia Consensus Conference. Ann Oncol 9: 811-819
62. Jordan K et al. (2007) Comparative activity of antiemetic drugs. Crit Rev Oncol Hematol 61: 162-175
63. Gralla RJ et al. (2003) Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: Results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. Ann Oncol 14: 1570-1577
64. 3 receptor antagonist: Results of a phase III, single-dose trial versus dolasetron. Cancer 98: 2473-2482
65. Aapro MS et al. (2006) A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy, Ann Oncol 17: 1441-1449
66. Cocquyt V et al. (2001) Comparison of L-758,298, a prodrug for the selective neurolokinin-1 antagonist, L-754,030, with ondransetron for the prevention of cisplatin-induced emesis. Eur J Cancer37: 835-842
67. Navari RM et al. (1999) Reduction of cisplatin-induced emesis by a selective neurokinin-1-receptor antagonist L-754,030-Antiemetic Trials Group. N Engl J Med 340: 190-195
68. Van Belle S et al. (2002) Prevention of cisplatin-induced acute and delayed emesis by selective neurokinin-1 antagonists, L-758,298 and MK-869. Cancer 94: 3032-3041
69. Campos D et al. (2001) Prevention of cisplatin-induced emesis by the oral neurokinin-1 antagonist, MK-869, in combination with granisetron and dexamethasone or with dexamethasone alone. J Clin Oncol 19: 1759-1767
70. Chawla SP et al. (2003) Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting. Cancer 97: 2290-3000
71. Poli-Bigelli S et al. (2003) Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting: Results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer 97: 3090-3098
72. Hesketh PJ et al. (2003) The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: A multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin.The aprepitant 052 study group. J Clin Oncol 21: 4112-4119
73. Warr DG et al. (2005) Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J Clin Oncol 23: 2822-2830
74. Schmoll HJ et al. (2006) Comparison of an aprepitant regimen with a multiple-day ondansetron regimen, both with dexamethasone, for antiemetic efficacy in high-dose cisplatin treatment. Ann Oncol 17: 4112-4119
75. Hesketh PJ et al. (1999) Randomized ppase II study of the neurokinin-1 receptor antagonist, GJ-11,974 in the control of cisplatin-induced emesis. J Clin Oncol 17: 338-343
76. De Witt R et al. (2004) The oral NK-1 antagonist aprepitant given with standard antiemetics provided protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: A combined analysis of 2 randomized, placebo-controlled phase III trials. Eur J Cancer 40: 403-410
77. Herrstedt J et al. (2005) Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting over multiple cycles of moderately emetogenic chemotherapy. Cancer 104: 1548-1555
78. Nygren P et al. (2005) Lack of effect of eprepitant on the pharmacokinetics of docetaxell in cancer patients. Cancer Chemother Pharmacol 55: 609-616
79. Apornwirat W et al. (2006) Multicenter, randomized, double-blind ondansetron controlled, dose-ranging parallel group trial of the neurokinin-1 receptor antagonist casopitant mesylate for chemotherapy-induced nausea/vomiting in patients receiving moderately emetogenic chemotherapy [abstract]. J Clin Oncol 24: 471s
80. Rolski J et al. (2006) Randomized phase II trial of the neurokinin-1 receptor antagonist casopitant mesylate with ondansetron/ dexamethasone for chemotherapy-induced nausea/vomiting in patients receiving highly emetogenic chemotherapy [abstract]. J Clin Oncol 24: 471s
81. Navari RM et al. (2007) A phase II trial of olanzapine, dexamethasone, and palonosetron for the prevention of chemotherapy-induced nausea and vomiting: A Hoosier oncology group study. Support Care Cancer 15: 1285-1291
82. Mandala M et al. (2005) Midazolam for acute emesis refractory to dexamethasone and granisetron after highly emetogenic chemotherapy: A phase II study. Support Care Cancer 13: 375-380
83. Rudd JA et al. (2006) Anti-emetic activity of ghrelin in ferrets exposed to the cytotoxic anti-cancer agent cisplatin. Neurosci Lett 392: 79-83
84. Roila F et al. (2006) Prevention of chemotherapy-and radiotherapy-induced emesis: Results of the 2004 Perugia International Antiemetic Consensus Conference. Ann Oncol 17: 20-28
85. Kris MG et al. (2006) ASCO Guidelines for Antiemetics in Oncology: Update 2006. J Clin Oncol 24: 2932-2947
86. Ballatori E et al. (1997) Clinical and methodological issues in antiemetic therapy: A worldwide survey of experts' opinions. Support Care Cancer 5: 269-273
87. Dranitsaris G et al. (2001) Implementing evidence based antiemetic guidelines in the oncology setting: Results of a 4-month prospective intervention study. Support Care Cancer 9: 611-618
88. Nolte MJ et al. (1998) Assuring the optimal use of serotonin antagonist antiemetics: The process for the development and implementation of institutional antiemetic guidelines at Memorial Sloan-Kettering Cancer Center. J Clin Oncol 16: 771-778
89. Grunberg SM et al. (2004) Incidence of chemotherapy-induced nausea and emesis after modern antiemetics. Cancer 100: 2261-2288
90. Grote T et al. (2006) Combination therapy for chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy: Palonosetron, dexamethasone, and aprepitant. J Support Oncol 4: 403-408
91. Grunberg SM et al. (2006) Prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with a 1-day 3-drug antiemetic regimen - preliminary report [abstract]. Support Care Cancer 14 596
92. Kangawa H et al. (1983) Neuromedin K: A novel mammalian tachykinin identified in porcine spinal cord. Biochem Biophys Res Commun 114: 533-540
93. Kimura S et al. (1983) Novel neuropeptides, neurokinin A and B isolated from porcine spinal cord. Proc Jpn Acad 59B: 101-104
94. Tatemoto K et al. (1985) Neuropeptide K: Isolation, structure and biological activities of a novel tachykinin. Biochem Biophys Res Commun 128: 947-953
95. Kage R et al. (1988) Neuropeptide y: A peptide isolated from rabbit intestine that is derived from χ-preprotachykinin. J Neurochem 50: 1412-1417
96. Maggi CA et al. (1993) Tachykinin receptors and tachykinin receptor antagonists. J Auton Pharmacol 13: 23-93